Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.52 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
| ▸ | PYGB | P11216 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15299087 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13542913 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8244688 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23816520 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14268507 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL24518019 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL147049 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13110610 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21610360 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL9914006 | 1.00 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498724-B1 | NUCLEIC ACID COMPLEX | KYOWA KIRIN CO LTD (JP) | 2023-06-21 | — | — | EP | disclosed |
| US-20210246157-A1 | CAMPTOTHECIN DERIVATIVES AND PREPARATION METHODS AND APPLICATIONS THEREOF | Sichuan Fushengyuan Technology Co., Ltd. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-10408783-B2 | Electrochemical methods and compounds for the detection of enzymes | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2019053700-A2 | FUNCTION-BASED PROBES FOR ENVIRONMENTAL MICROBIOME ANALYSIS AND METHODS OF MAKING AND USING THE SAME | BATTELLE MEMORIAL INSTITUTE (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10202469-B2 | Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same | GLYTECH, INC. (KP) | 2019-02-12 | — | — | US | disclosed |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
| US-9879097-B2 | Method for producing activated sugar chain derivative and activated sugar chain derivative produced therefrom | GLYTECH, INC. (JP) | 2018-01-30 | — | — | US | disclosed |
| EP-2780352-B1 | MANNOSYLATED COMPOUNDS USEFUL FOR THE PREVENTION AND THE TREATMENT OF INFECTIOUS DISEASES | UNIV STRASBOURG (FR) | 2017-11-08 | — | — | EP | disclosed |
| EP-2762489-A9 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Glytech, Inc. (JP) | 2015-02-11 | — | — | EP | disclosed |
| US-20140336116-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GLYTECH, INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2762489-A1 | GLYCOSYLATED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Glytech, Inc. (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-2414372-B1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | MAX PLANCK GESELLSCHAFT (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-8536153-B2 | Chemical synthesis of phosphatidylinositol mannoside glycans from Mycobacterium tuberculosis | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8252909-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8163705-B2 | Glycolipid and use thereof | RIKEN (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011014715-A2 | FLUOROPOLYMER COMPOSITIONS CONTAINING A POLYOL COMPOUND AND METHODS OF MAKING THEM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7632941-B2 | novel cyclodextrin derivatives, polysubstituted but also monosubstituted, in primary alcohol position by reacting halogenated cyclodextrin with aminoalkanethiol or the salt of aminoalklanethio to form intermediate, then with an isothiocyanate containing biorecognition element such as amino acid, peptide | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | FECH, SLC19A1, SLC40A1 | LGALS1 3977/4885LGALS3 4453/4885LGALS9 3026/4885 |
| US-10202469-B2 | Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same | SI, ENGASE, DNPEP | LGALS1 1064/4885LGALS3 1836/4885LGALS9 830/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | LGALS1 3977/4885LGALS3 4453/4885LGALS9 3026/4885 |
| US-20140336116-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GIPR, SSTR4, SSTR5 | LGALS1 638/4885LGALS3 671/4885LGALS9 751/4885 |
| US-10408783-B2 | Electrochemical methods and compounds for the detection of enzymes | EPX, DNASE1, DERA | LGALS1 1301/4885LGALS3 1105/4885LGALS9 1567/4885 |
| US-20210246157-A1 | CAMPTOTHECIN DERIVATIVES AND PREPARATION METHODS AND APPLICATIONS THEREOF | TOP1, TOP2A, TOP2B | LGALS1 1344/4885LGALS3 1081/4885LGALS9 1765/4885 |
| US-20090221516-A1 | NOVEL GLYCOLIPID AND USE THEREOF | IL4, IL2, IL5 | LGALS1 146/4885LGALS3 320/4885LGALS9 296/4885 |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | FECH, TFRC, FTH1 | LGALS1 2325/4885LGALS3 2758/4885LGALS9 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.